Moreover, the 36-month beta value for ANTX is -0.22. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ANTX is 19.32M and currently, short sellers hold a 0.69% of that float. On November 14, 2024, ANTX’s average trading volume was 426.72K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ANTX) stock’s latest price update
The stock of AN2 Therapeutics Inc (NASDAQ: ANTX) has decreased by -4.72 when compared to last closing price of 1.06.Despite this, the company has seen a loss of -8.18% in its stock price over the last five trading days. businesswire.com reported 2024-11-13 that MENLO PARK, Calif.–(BUSINESS WIRE)–AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the quarter ended September 30, 2024 and provided an update from its ongoing analysis of data from the Phase 2 portion of the EBO-301 trial. “Treatment options for patients with refractory MAC lung disease are extremely limited. Many of these.
ANTX’s Market Performance
AN2 Therapeutics Inc (ANTX) has seen a -8.18% fall in stock performance for the week, with a -3.81% decline in the past month and a -0.98% plunge in the past quarter. The volatility ratio for the week is 4.14%, and the volatility levels for the past 30 days are at 3.33% for ANTX. The simple moving average for the past 20 days is -6.26% for ANTX’s stock, with a -64.09% simple moving average for the past 200 days.
Analysts’ Opinion of ANTX
Many brokerage firms have already submitted their reports for ANTX stocks, with Leerink Partners repeating the rating for ANTX by listing it as a “Market Perform.” The predicted price for ANTX in the upcoming period, according to Leerink Partners is $1 based on the research report published on August 09, 2024 of the current year 2024.
Leerink Partners gave a rating of “Outperform” to ANTX, setting the target price at $5 in the report published on July 03rd of the current year.
ANTX Trading at -4.65% from the 50-Day Moving Average
After a stumble in the market that brought ANTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.45% of loss for the given period.
Volatility was left at 3.33%, however, over the last 30 days, the volatility rate increased by 4.14%, as shares sank -4.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.94% lower at present.
During the last 5 trading sessions, ANTX fell by -8.18%, which changed the moving average for the period of 200-days by -94.80% in comparison to the 20-day moving average, which settled at $1.0775. In addition, AN2 Therapeutics Inc saw -95.07% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANTX starting from RA Capital Healthcare Fund LP, who proposed sale 1,699,998 shares at the price of $1.00 back on Aug 15 ’24. After this action, RA Capital Healthcare Fund LP now owns shares of AN2 Therapeutics Inc, valued at $1,699,999 using the latest closing price.
RA Capital Nexus Fund II, L.P., the Affiliate of AN2 Therapeutics Inc, proposed sale 299,999 shares at $1.02 during a trade that took place back on Aug 15 ’24, which means that RA Capital Nexus Fund II, L.P. is holding shares at $305,998 based on the most recent closing price.
Stock Fundamentals for ANTX
Current profitability levels for the company are sitting at:
- -889.64 for the present operating margin
- 0.5 for the gross margin
The net margin for AN2 Therapeutics Inc stands at -808.21. The total capital return value is set at -0.72. Equity return is now at value -69.48, with -62.35 for asset returns.
Currently, EBITDA for the company is 4.9 million with net debt to EBITDA at 0.53. When we switch over and look at the enterprise to sales, we see a ratio of 42.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.61.
Conclusion
To wrap up, the performance of AN2 Therapeutics Inc (ANTX) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
